Fig. 2From: Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA CohortProportion of patients with decreased dose for each bDMARD. ABA abatacept, ADA adalimumab, CZP certolizumab, ETN etanercept, GOL golimumab, IFX infliximab, RTX rituximab, TOC tocilizumabBack to article page